statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

How Is The Market Feeling About Candel Therapeutics?

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Candel Therapeutics Inc trading halted, volatility trading pause

Candel Therapeutics sees surge in shares amid robust volume, buoyed by promising interim data from CAN-2409 phase 2 trial for non-metastatic prostate cancer. Exciting developments continue with...

What's Going On With Candel Therapeutics Stock On Friday?

Acciones al alza
Tevogen Bio Holdings (NASDAQ:TVGN) ganaron un 92,75% para establecerse en los 5,05 d lares durante la sesi n del pre-market del jueves.
Candel Therapeutics (NASDAQ:CADL) avanzaron un...

12 acciones de salud en movimiento durante la preapertura del 04/04/2024

Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in...

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics reports Q4 EPS (38c) vs (18c) last year

On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in...

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

Candel Therapeutics presents updated data from Phase 1b trial of CAN-3110

The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial.The serial procedures were well tolerated without observed dose-limiting...

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
CADL stock results show that Candel Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023

Candel Therapeutics, Inc. is a late clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Volume	211.00
52-Wk High	$11.40
52-Wk Low	$0.66

CADL Candel Therapeutics Inc

About

Feed

News

Earnings

Fundamentals